Kramer Michael R, Bhagat Nishi, Back Susan J, Poznick Laura, Forsberg Flemming, Darge Kassa, Eisenbrey John R
School of Medicine, Temple University, Philadelphia, PA, USA.
Department of Radiology, Thomas Jefferson University, 132 South 10th St., Philadelphia, PA, 19107, USA.
Pediatr Radiol. 2018 Jan;48(1):101-108. doi: 10.1007/s00247-017-3976-9. Epub 2017 Sep 11.
In pediatrics, contrast-enhanced ultrasound offers high-quality imaging with an excellent safety profile.
To investigate the effects of varying intravenous administration setups on in vitro enhancement and concentration of two commercially available ultrasound contrast agents, taking into consideration potential pediatric applications.
We quantified in vitro enhancement using a flow phantom (ATS Laboratories, Bridgeport, CT) and Acuson S3000 ultrasound system (Siemens Healthineers, Mountain View, CA) with a 9L4 probe in Cadence pulse sequencing mode. We determined microbubble concentration with an LSRII flow cytometer (BD Biosciences, San Jose, CA). We investigated Optison (GE Healthcare, Princeton, NJ) and Lumason (Bracco, Geneva, Switzerland) ultrasound contrast agents. The ultrasound (US) contrast agent was injected via a 1 mL syringe and flushed with 5 mL of saline through a 22-gauge diffusion catheter (BD Medical, Franklin Lakes, NJ) with the following variations: in-line injection through a 3-way stopcock with and without a neutral displacement connector (ICU Medical, San Clemente, CA), perpendicular through a 3-way stopcock with and without a connector, and without a 3-way stopcock. We also conducted injections through a 22-gauge standard angiocatheter.
Injection through the connector and perpendicular injection via the 3-way stopcock resulted in significant decreases in enhancement for both ultrasound contrast agents (P<0.0001). Injection through the connector resulted in significant decrease in concentration for Optison (P<0.05). Neither addition of the 3-way stopcock (P>0.24) nor use of a pediatric diffusion catheter (P>0.28) affected the enhancement.
Ultrasound contrast agent enhancement depends on the administration route, although some effects appear to be specific to the ultrasound contrast agent used. To avoid loss of enhancement, neutral displacement connectors and perpendicular injection should be avoided.
在儿科领域,超声造影可提供高质量成像,且安全性极佳。
考虑到潜在的儿科应用,研究不同静脉给药设置对两种市售超声造影剂体外增强效果和浓度的影响。
我们使用流动模型(ATS实验室,布里奇波特,康涅狄格州)和配备9L4探头的Acuson S3000超声系统(西门子医疗,山景城,加利福尼亚州),以Cadence脉冲序列模式对体外增强效果进行量化。我们使用LSRII流式细胞仪(BD生物科学公司,圣何塞,加利福尼亚州)测定微泡浓度。我们研究了Optison(通用电气医疗集团,普林斯顿,新泽西州)和Lumason(博莱科公司,日内瓦,瑞士)超声造影剂。超声(US)造影剂通过1 mL注射器注射,并通过22号弥散导管(BD医疗公司,富兰克林湖,新泽西州)用5 mL生理盐水冲洗,有以下几种变化:通过带和不带中性位移连接器(ICU医疗公司,圣克莱门特,加利福尼亚州)的三通旋塞进行在线注射,通过带和不带连接器的三通旋塞进行垂直注射,以及不使用三通旋塞。我们还通过22号标准血管导管进行注射。
通过连接器注射以及通过三通旋塞进行垂直注射,两种超声造影剂的增强效果均显著降低(P<0.0001)。通过连接器注射导致Optison的浓度显著降低(P<0.05)。添加三通旋塞(P>0.24)和使用儿科弥散导管(P>0.28)均未影响增强效果。
超声造影剂的增强效果取决于给药途径,尽管某些影响似乎特定于所使用的超声造影剂。为避免增强效果丧失,应避免使用中性位移连接器和垂直注射。